MarketCap
Facebook
X
Telegram
Sage Therapeutics Balance Sheet 2024-2011 | SAGE
Brief overview of Sage Therapeutics's balance sheet structure
Balance sheet changes are traced across five available annual reports between 2020 and 2024.
Assets declined from $2.2 billion to $547.2 million, or -74.7%. The contraction calls for context such as disposals, restructuring or weaker operations.
Funding shifted toward liabilities: they gained -5.5%, compared with -74.7% for assets.
Equity accounts for 85% of assets. Against the initial 96%, the capital position looks resilient.
The balance sheet holds more cash than interest-bearing debt; net debt is -$69.2 million, indicating minimal leverage.
The cash reserve occupies 14.8% of the balance sheet, previously 76.9%. It is one marker of short-term resilience.
Retained earnings remain negative at -$3 billion. This may reflect past losses or substantial shareholder distributions, so earnings and buybacks provide important context.
Overall picture
Sage Therapeutics's balance sheet profile is moderate. It should be considered alongside profitability, cash flow and liability maturities.
Annual Balance Sheet Sage Therapeutics
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-69.2 M | - | -151 M | -276 M | - | -89.6 M | -191 M | -306 M | -169 M | -187 M | -128 M | -8.07 M | -2.8 M | - |
Long Term Debt |
10.5 M | - | 4.49 M | 11 M | - | - | - | - | - | - | - | - | - | - |
Long Term Debt Current |
1.32 M | 5.16 M | 7.64 M | 7.47 M | 8.66 M | 10.2 M | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | 27.4 M | 3.7 M | 2.51 M | 845 K | 14 K | 23 K | 37.8 M | 15 M | - |
Total Current Liabilities |
71.6 M | 82.7 M | 99.3 M | 85.2 M | 67.2 M | 112 M | 86 M | 52 M | 35.2 M | 15.3 M | 7.76 M | - | - | - |
Total Liabilities |
82.1 M | 82.7 M | 104 M | 96.3 M | 86.9 M | 139 M | 89.7 M | 54.5 M | 36 M | 15.3 M | 7.78 M | 40.1 M | 16.4 M | - |
Retained Earnings |
-2.97 B | -2.57 B | -2.03 B | -1.5 B | -1.04 B | -1.64 B | -963 M | -590 M | -320 M | -161 M | -66.8 M | -31.7 M | -13.4 M | - |
Total Assets |
547 M | 882 M | 1.36 B | 1.83 B | 2.16 B | 1.08 B | 953 M | 530 M | 405 M | 189 M | 130 M | 8.53 M | 3 M | - |
Cash and Cash Equivalents |
81 M | 71 M | 163 M | 294 M | 1.66 B | 127 M | 191 M | 306 M | 169 M | 187 M | 128 M | 8.07 M | 2.8 M | - |
Book Value |
465 M | 800 M | 1.25 B | 1.73 B | 2.07 B | 945 M | 863 M | 475 M | 369 M | 174 M | 122 M | -31.5 M | -13.4 M | - |
Total Shareholders Equity |
465 M | 800 M | 1.25 B | 1.73 B | 2.07 B | 945 M | 863 M | 475 M | 369 M | 174 M | 122 M | -31.5 M | -13.4 M | - |
All numbers in USD currency
Quarterly Balance Sheet Sage Therapeutics
| 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
9.54 M | 10 M | 10.5 M | 10.2 M | - | - | - | - | 1 M | 2.76 M | 4.49 M | 6.16 M | - | 9.4 M | 11 M | 12.5 M | 14 M | 15.4 M | 19.4 M | 19.4 M | 19.4 M | 19.4 M | 26.8 M | 26.8 M | 26.8 M | 26.8 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
54.2 M | 59.8 M | 82.1 M | 70.6 M | 69 M | 61.8 M | 82.7 M | 133 M | 97.9 M | 87.6 M | 104 M | 106 M | - | 87.2 M | 96.3 M | 91.5 M | 86 M | 77.4 M | 86.9 M | 86.9 M | 86.9 M | 86.9 M | 139 M | 139 M | 139 M | 139 M | 89.7 M | 89.7 M | 89.7 M | 89.7 M | 54.5 M | 54.5 M | 54.5 M | 54.5 M | 36 M | 36 M | 36 M | 36 M | 15.3 M | 15.3 M | 15.3 M | 15.3 M | 7.78 M | 7.78 M | 7.78 M | 7.78 M | 2.36 M | 2.36 M | 2.36 M | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-3.08 B | -3.03 B | -2.97 B | -2.87 B | -2.78 B | -2.68 B | -2.57 B | -2.54 B | -2.34 B | -2.17 B | -2.03 B | -1.88 B | - | -1.62 B | -1.5 B | -1.37 B | -1.24 B | -1.13 B | -1.04 B | -1.04 B | -1.04 B | -1.04 B | -1.64 B | -1.64 B | -1.64 B | -1.64 B | -963 M | -963 M | -963 M | -963 M | -590 M | -590 M | -590 M | -590 M | -320 M | -320 M | -320 M | -320 M | -161 M | -161 M | -161 M | -161 M | -66.8 M | -66.8 M | -66.8 M | -66.8 M | -31.7 M | -31.7 M | -31.7 M | - | - | - | - | - | - | - | - | - |
Total Assets |
423 M | 470 M | 547 M | 622 M | 697 M | 768 M | 882 M | 950 M | 1.08 B | 1.22 B | 1.36 B | 1.49 B | - | 1.71 B | 1.83 B | 1.93 B | 2.02 B | 2.08 B | 2.16 B | 2.16 B | 2.16 B | 2.16 B | 1.08 B | 1.08 B | 1.08 B | 1.08 B | 953 M | 953 M | 953 M | 953 M | 530 M | 530 M | 530 M | 530 M | 405 M | 405 M | 405 M | 405 M | 189 M | 189 M | 189 M | 189 M | 130 M | 130 M | 130 M | 130 M | 8.53 M | 8.53 M | 8.53 M | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
67.5 M | 45.2 M | 81 M | 99.6 M | 99.9 M | 173 M | 71 M | 149 M | 121 M | 207 M | 163 M | 200 M | - | 179 M | 294 M | 422 M | 514 M | 899 M | 1.66 B | 1.66 B | 1.66 B | 1.66 B | 127 M | 127 M | 127 M | 127 M | 191 M | 191 M | 191 M | 191 M | 306 M | 306 M | 306 M | 306 M | 169 M | 169 M | 169 M | 169 M | 187 M | 187 M | 187 M | 187 M | 128 M | 128 M | 128 M | 128 M | 8.07 M | 8.07 M | 8.07 M | - | 2.8 M | - | - | - | 2.84 M | - | - | - |
Book Value |
369 M | 410 M | 465 M | 552 M | 628 M | 706 M | 800 M | 817 M | 984 M | 1.13 B | 1.25 B | 1.38 B | - | 1.62 B | 1.73 B | 1.84 B | 1.93 B | 2 B | 2.07 B | 2.07 B | 2.07 B | 2.07 B | 945 M | 945 M | 945 M | 945 M | 863 M | 863 M | 863 M | 863 M | 475 M | 475 M | 475 M | 475 M | 369 M | 369 M | 369 M | 369 M | 174 M | 174 M | 174 M | 174 M | 122 M | 122 M | 122 M | 122 M | 6.17 M | 6.17 M | 6.17 M | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
369 M | 410 M | 465 M | 552 M | 628 M | 706 M | 800 M | 817 M | 984 M | 1.13 B | 1.25 B | 1.38 B | 1.5 B | 1.62 B | 1.73 B | 1.84 B | 1.93 B | 2 B | 2.07 B | 2.07 B | 2.07 B | 2.07 B | 945 M | 945 M | 945 M | 945 M | 863 M | 863 M | 863 M | 863 M | 475 M | 475 M | 475 M | 475 M | 369 M | 369 M | 369 M | 369 M | 174 M | 174 M | 174 M | 174 M | 122 M | 122 M | 122 M | 122 M | -31.5 M | -31.5 M | -31.5 M | - | -13.4 M | - | - | - | -3.76 M | - | - | - |
All numbers in USD currency
Balance Sheet is a fundamental financial report of Sage Therapeutics, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
USA
Canada
China
Israel
France
Germany
Britain
Russia
Belgium
Cayman-islands
